Celgene Corporation ( CELG ) recently announced encouraging results on its candidate apremilast from a phase III study (PALACE-1: n~500), which evaluated patients suffering from
Celgene Corporation ( CELG ) recently announced encouraging results on its candidate apremilast from a phase III study (PALACE-1: n~500), which evaluated patients suffering from